Device Trial Radar · NCT06520124
Stellest Lens Wear in Adult Progressing Myopes
Last checked: Nov 19, 2026Latest source record: Feb 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
Oct 17, 2024
Primary completion
Dec 30, 2027
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- University of UlsterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Essilor International
- First posted
- Jul 25, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
It is expected that myopia progression stabilises in the late teenage years, however, some studies report that myopia progression continues through early adulthood in as many as one third of myopes. Similarly, there are reports of myopia commencing in early adulthood. Although the rate of progression is slower than that occurring in childhood, between 20-35% of adults aged between 20-30 years were reported to progress by at least -1.00D over a five year period. Given that every dioptre increase in myopia results in an increased overall lifetime risk of serious ocular pathology, it seems opportune to investigate whether myopia management treatments designed to slow myopia progression in childhood could be beneficial for progressing adult myopes. The proposed study will conduct a prospective, randomised, paired-eye, trial with cross-over to evaluate the efficacy of Essilor Stellest myopia management spectacle lenses on the progression of myopia in adults aged between 18-40 years. The outcomes from the trial will provide novel evidence regarding the utility of these lenses in an adult population.
Conditions
- Myopia, Progressive
Interventions
Essilor® Stellest® spectacle lensDevice
Spectacle lens with highly aspherical lenslets.
Single-vision spectacle lensDevice
Standard single-vision distance spectacle lens.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in axial length (mm)Time frame: 2 years
- Change in cycloplegic autorefraction (D)Time frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ulster University
Coleraine, County Londonderry, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.